SOURCE: BioMedical Technology Solutions Holdings

September 07, 2010 09:30 ET

BioMedical Technology Solutions Holdings Prepares for Growth With Addition of Manny Losada to Board of Directors

ENGLEWOOD, CO--(Marketwire - September 7, 2010) -  BioMedical Technology Solutions Holdings, Inc. ("BMTS") (OTCBB: BMTL) is pleased to announce that Manny Losada, President of MedPro Associates of Idaho Springs, CO, has agreed to join BMTS as a member of its Board of Directors as of September 1, 2010.

Mr. Losada brings over 25 years of senior leadership experience in distribution and manufacturing with Fortune 500 healthcare companies. Along with his 25 years of domestic experience, Mr. Losada has extensive international experience as well. He has conducted business globally including negotiations in Asia, Hong Kong, Beijing, Shanghai, Taiwan, Macau, Singapore, Spain, Portugal, Germany, Argentina, Brazil and Canada.

Mr. Losada currently serves as President of MedPro Associates, one of the nation's largest national manufacturer's representation organizations specializing in the healthcare markets. MedPro represents leading manufacturers who sell their products through distribution agreements or directly into the hospital, physician, long-term care, dental and veterinary markets. As President he is responsible for MedPro's strategic growth and business development.

Prior to joining MedPro, Mr. Losada held key senior management positions at Medical Actions Industries, B. Braun Medical, Henry Schein and Caligor/MicrobioMedics, Inc. During his time at Caligor/MicrobioMedics, Mr. Losada was heavily involved in mergers and acquisitions where he successfully completed 5 acquisitions of regional hospital suppliers to support a 5-year, double digit growth rate. Mr. Losada is highly respected across the industry as a proven leader who emphasizes motivation, individual, team and organizational accountability. 

Don Cox, President and CEO of BMTS, stated, "We are truly excited that Manny has agreed to join our Board of Directors. With his tremendous experience and proven leadership, Manny understands what is needed to develop long term strategic growth. I have gotten to know Manny very well over the past few years. He is a strategic thinker that has a depth of the knowledge on the diverse healthcare industries that is extremely difficult to find. As we continue our expansion both domestically and internationally, Manny is going to be an invaluable resource to our team."

About BioMedical Technology Solutions Holdings, Inc.

BioMedical Technology Solutions Holdings, Inc., located in Englewood, Colorado, sells the Demolizer® II through its wholly owned subsidiary BioMedical Technology Solutions, Inc. BMTS' patented Demolizer® Technology converts infectious biomedical waste into non-infectious material. BMTS' products provide biomedical waste treatment solutions for the over 1,000,000 low to medium volume medical waste generators in the US and a global market five times larger than the US. For more information, visit http://www.bmtscorp.com/ or call 866-525-2687.

About the Demolizer® II

The Demolizer® II is the GREEN alternative to biomedical waste disposal. The device is the only patented, portable, and self-contained system able to process both sharps and typical red bag biomedical waste onsite. The processed waste is rendered sterile and discarded as common trash eliminating up to 100% of the cost associated with its disposal. The Demolizer® II meets or exceeds all EPA and CDC guidelines and is approved or meets treatment requirements in 48 states after review by 80 governmental agencies. The device uses no chemicals or liquids, plugs into a normal outlet through a surge protector, and automatically records and prints state required documentation. The Demolizer® II provides a safer, more environmentally GREEN method for biomedical waste disposal.

Safe Harbor for Forward-Looking Statements

The statements contained in this press release may include certain projections and forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements involve a number of risks and uncertainties. Such statements reflect the Company's current views with respect to future events and financial performance. No assurances can be given however, that these events will occur or that such expectations will be achieved and that actual results could differ materially from those described. Actual results of future operations of BioMedical Technology Solutions Holdings, Inc. may differ materially from those indicated by these forward-looking statements as a result of various important factors.

Contact Information

  • Contact:
    Don Cox
    BMTL President and CEO
    (303) 653-0100